Zai Lab Announces Participation in March Investor Conference Read more about Zai Lab Announces Participation in March Investor Conference
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024 Read more about Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC Read more about Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
Zai Lab Announces Participation in January Investor Conference Read more about Zai Lab Announces Participation in January Investor Conference
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List Read more about Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
Zai Lab Announces Participation in November Investor Conferences Read more about Zai Lab Announces Participation in November Investor Conferences
Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023 Read more about Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China Read more about Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China Read more about Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
Zai Lab Announces Participation in September Investor Conferences Read more about Zai Lab Announces Participation in September Investor Conferences